empty

New ticagrelor dose

The EC has granted marketing authorisation for a 60mg dose of ticagrelor (Brilique) for patients who suffered a heart attack at least one year previously and who are considered at high risk of another atherothrombotic event. The new dose may be started as continuation therapy after one year’s treatment with ticagrelor 90mg and aspirin or another dual antiplatelet regimen.

Recommended

Clinical review: Antihypertensive medication

NICE recommends Tremfya




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.